ATROPINE JUNO atropine sulfate monohydrate 1.2mg/1mL injection BP ampoule

Valsts: Austrālija

Valoda: angļu

Klimata pārmaiņas: Department of Health (Therapeutic Goods Administration)

Aktīvā sastāvdaļa:

atropine sulfate monohydrate, Quantity: 1.2 mg/mL

Pieejams no:

Juno Pharmaceuticals Pty Ltd

Zāļu forma:

Injection, solution

Kompozīcija:

Excipient Ingredients: sodium chloride; water for injections; hydrochloric acid

Ievadīšanas:

Intramuscular, Intravenous, Subcutaneous

Vienības iepakojumā:

1mL x 50

Receptes veids:

(S4) Prescription Only Medicine

Ārstēšanas norādes:

INDICATIONS AS AT 30 SEPTEMBER 2003 : Surgery: Atropine may be given as a pre-anaesthetic medication to inhibit excessive salivary and bronchial secretions and to diminish the risk of vagal inhibition of the heart. The use of atropine as an antisialogogue is rarely necessary since the introduction of halothane and similar anaesthetics in place of ether anaesthesia. After surgery atropine may also be administered concurrently with anticholinesterase agents (e.g. neostigmine, physostigmine) when used to terminate curarisation to counteract the adverse muscarinic effects of these drugs. Cardiopulmonary resuscitation: Atropine may be used during cardiopulmonary resuscitation to treat sinus bradycardia and associated hypotension, and increased ventricular irritability. Anticholinesterase Poisoning: Atropine sulfate is also used in the treatment of sinus bradycardia induced by organophosphate pesticides, Amanita muscaria mushrooms or other compounds with anticholinesterase activity. A cholinesterase reactivator, e.g. pralidoxime iodide, may be given concurrently.

Produktu pārskats:

Visual Identification: Clear, colourless, particle-free solution.; Container Type: Ampoule; Container Material: PE; Container Life Time: 18 Months; Container Temperature: Store below 25 degrees Celsius

Autorizācija statuss:

Registered

Autorizācija datums:

2022-07-01